Additive/synergistic: In vitro: EZH2 knock-down increased sensitivity to cisplatin. In vivo: siRNA-EZH2 coated nanoparticles and cisplatin inhibited tumor growth more than nanoparticles with control siRNA and cisplatin. Here, EZH2 is linked to neoplasm.